Key result
Carvedilol improves hemodynamics and slows cardiac remodeling more than metoprolol tartrate in CHF and AF.
Why the study?
The study evaluated the effects of beta-blockers on myocardial remodeling and endothelial adhesive function in patients with chronic heart failure and atrial fibrillation of ischemic origin.
Does carvedilol improve myocardial remodeling and endothelial function compared to metoprolol tartrate in patients with chronic heart failure and atrial fibrillation of ischemic origin?
RCT (n=77)
randomized
Does carvedilol improve myocardial remodeling and endothelial function compared to metoprolol tartrate in patients with chronic heart failure and atrial fibrillation of ischemic origin?
Carvedilol provides superior hemodynamic and endothelial-protective effects compared to metoprolol tartrate in patients with ischemic heart failure and atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Favors carvedilol over metoprolol tartrate in ischemic CHF with AF; extends randomized beta-blocker comparisons to this population.
Zakirova et al. (2020) conducted an RCT in chronic heart failure and atrial fibrillation of ischemic origin (n=77). carvedilol vs. metoprolol tartrate was evaluated on myocardial remodeling and endothelial adhesive function (sVCAM-1 and sE-selectin). Carvedilol improved intracardiac hemodynamics, slowed cardiac remodeling, and reduced endothelial adhesion molecules more significantly than metoprolol tartrate in patients with CHF and AF.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: